The UK drugmaker's opposition meant the offer fell short of the 90 per cent threshold needed for approval
from Latest News https://ift.tt/2ZPOdNG
Friday, 3 December 2021
AstraZeneca blocks Advent's $7.6-bn buyout of Swedish Orphan Biovitrum
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment